$PAOG Goldman Small Cap Research Gives $0.015 PT +350% Upside
PAO Group Inc.
(STOCK: PAOG)
Current Price: $0.0031
Goldman Small Cap Research Price Target:
$0.015
Float: 620M
About The Company
PAO Group, Inc. is an emerging cannabis and CBD company targeting growth via two tracks. The Company is in the early stages of developing a cannabis extract-based therapy to treat various respiratory diseases and illnesses, PAOG also owns a growing cannabis cultivation operation focused on hemp cultivation.
Investment Highlights:
Conclusion: PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones. Thus, we have now introduced a 12-month target of $0.015, a nearly 5x return from current levels
Future Developments: This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Next steps include engaging a CRO to initiate the process for potential FDA approval of RespRx, its COPD treatment, representing an estimated $14.1B market by 2025. We expect this application to be fast-tracked, given that the use of CBDs to treat this disease is novel and based on a natural (and likely safer) product.
Price Target/ Higher Valuation: By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target. This targeted valuation is in line with IND-filling stocks. Moreover, with no long term debt on the books, PAOG has significant funding flexibility to continue on its R&D paths.
The Bullish Case For PAOG
Substantial Multi-Billion Dollar Market Opportunity
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Market analyst Goldman Small Cap Research slapped on a 12-month target of $0.015, a nearly 5x return from current levels.
The Bottom Line:
PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones.
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target.
If you’re looking for a growth/ground floor opportunity in the multi-billion dollar CBD sector, PAOG if the opportunity you've been waiting for!By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)
(STOCK: PAOG)
Current Price: $0.0031
Goldman Small Cap Research Price Target:
$0.015
Float: 620M
About The Company
PAO Group, Inc. is an emerging cannabis and CBD company targeting growth via two tracks. The Company is in the early stages of developing a cannabis extract-based therapy to treat various respiratory diseases and illnesses, PAOG also owns a growing cannabis cultivation operation focused on hemp cultivation.
Investment Highlights:
Conclusion: PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones. Thus, we have now introduced a 12-month target of $0.015, a nearly 5x return from current levels
Future Developments: This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Next steps include engaging a CRO to initiate the process for potential FDA approval of RespRx, its COPD treatment, representing an estimated $14.1B market by 2025. We expect this application to be fast-tracked, given that the use of CBDs to treat this disease is novel and based on a natural (and likely safer) product.
Price Target/ Higher Valuation: By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target. This targeted valuation is in line with IND-filling stocks. Moreover, with no long term debt on the books, PAOG has significant funding flexibility to continue on its R&D paths.
The Bullish Case For PAOG
Substantial Multi-Billion Dollar Market Opportunity
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
Market analyst Goldman Small Cap Research slapped on a 12-month target of $0.015, a nearly 5x return from current levels.
The Bottom Line:
PAO Group currently trades above its 50-day and 200 day moving averages. This bullish status, along with its recently updated financials reporting, should prompt the shares to reach new levels. Moreover, a review of the financials lends us greater confidence in the Company’s R&D financing capabilities and the achievement of key milestones.
This emerging CBD Pharma company is set to evolve from a promising preclinical firm toward a Phase I development path entity. PAOG has multiple shots on goal as it seeks to treat two major respiratory diseases that each represent billions in potential market sizes.
By running concurrent development programs resulting in two IND filings within the next year, we believe that such events could support a $20M valuation, or a $0.015 price target.
If you’re looking for a growth/ground floor opportunity in the multi-billion dollar CBD sector, PAOG if the opportunity you've been waiting for!By Viewing this Content, you Agree that you Have Read and are in Full Understanding of both our Disclaimer & Privacy Policy(*Remember to use a Stop-Loss Order to protect your gains, as well as limit possible losses.)